Safety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapy

Norbert Pfeiffer, Maria-Luise Scherzer, Hubert Maier, Sonja Schoelzel, Mark C Jasek, Jeanette A Stewart, William C Stewart, Norbert Pfeiffer, Maria-Luise Scherzer, Hubert Maier, Sonja Schoelzel, Mark C Jasek, Jeanette A Stewart, William C Stewart

Abstract

Purpose: To assess the safety and efficacy of changing to the travoprost/timolol fixed combination (TTFC) from other mono- or adjunctive therapies.

Patients and methods: A prospective, open-label, observational cohort of primary open-angle glaucoma and ocular hypertensive patients whose intraocular pressure (IOP) was uncontrolled on prior therapy or was not on target. Patients were changed from prior mono- or adjunctive treatment at Day 0 to TTFC dosed every evening and underwent active treatment efficacy and safety evaluations at Week 12.

Results: In 474/522 (91%) patients who completed this trial an IOP (mm Hg) of 21.9 +/- 2.0 on prior treatment was reduced by TTFC at Month 3: from all prior treatments 5.6 +/- 2.6; from monotherapy 5.9 +/- 2.3; from adjunctive treatments 4.5 +/- 2.9; and from several of the most frequent individual treatments: timolol 5.7 +/- 2.2; latanoprost 6.3 +/- 2.6; and latanoprost/timolol fixed combination 4.4 +/- 1.9. Ocular hyperemia was the most frequent adverse effect (n = 21, 4%). Both patients and physicians preferred TTFC compared to all prior and common individual treatments. The solicited symptom survey showed, following a modified Bonferroni correction (alpha/5), a reduced incidence with TTFC of ocular pain (P = 0.01) while the prior medicine had a lower incidence of burning on instillation (P < 0.001).

Conclusions: Changing patients from prior mono- or adjunctive therapy to TTFC can provide on average a further reduction in IOP while demonstrating a favorable safety profile and a high patient preference.

Keywords: efficacy; intraocular pressure; ocular hypertension; primary open-angle glaucoma; safety; travoprost/timolol fixed combination.

Figures

Figure 1
Figure 1
The intraocular pressure (IOP) decrease from baseline (Visit 1), irrespective of prior therapy, for the Per Protocol population.

References

    1. Barnebey HS, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol. 2005;140(1):1–7.
    1. Silverman SL. From randomized controlled trials to observational studies. Am J Med. 2009;122(2):114–120.
    1. Fletcher AE. Controversy over “contradiction”: should randomized trials always trump observational studies? Am J Ophthalmol. 2009;147(3):384–386.
    1. Book SA. Essentials of Statistics. New York, NY: McGraw Hill Book Company; 1978. pp. 117–122.pp. 205–215.
    1. Duff GR. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intraocular pressure. Acta Ophthalmologica. 1987;65(5):618–621.
    1. Miller RG. Beyond ANOVA: Basics of Applied Statistics. New York, NY: Chapman and Hall/CRC; 1998. pp. 74–76.
    1. Siegel S. Nonparametric Statistics for the Behavioral Sciences. New York, NY: McGraw Hill Book Company; 1956. pp. 63–67.
    1. Zimmerman TJ, Stewart WC, for Latanoprost AXIS Study Group Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther. 2003;19(5):405–415.
    1. Hamacher T, Schinzel M, Schölzel-Klatt A, et al. Short-term efficacy and safety in glaucoma patients changed to the latanoprost 0.005%/timolol maleate 0.5% fixed combination from mono- and adjunctive therapies. Br J Ophthalmol. 2004;88(10):1295–1298.
    1. Konstas AGP, Bányai L, Blask K-D, et al. Intraocular pressure and safety in glaucoma patients switching to latanoprost/timolol maleate fixed combination from mono- and adjunctive therapies. J Ocul Pharmacol Ther. 2004;20(5):375–382.
    1. Haverkamp F, Wuensch S, Fuchs M, Stewart WC. Intraocular pressure, safety and quality of life in glaucoma patients switching to latanoprost from adjunctive and monotherapy treatments. Eur J Ophthalmol. 2004;14(5):407–415.
    1. Bayer A, Weiler W, Oeverhaus U, et al. Two-year follow-up of latanoprost 0.005% monotherapy after changing from previous glaucoma therapies. J Ocul Pharmacol Ther. 2004;20(6):470–478.
    1. Dunker S, Schmucker A, Maier H. Tolerability, quality of life, and persistency of use in patients with glaucoma who are switched to the fixed combination of latanoprost and timolol. Adv Ther. 2007;24(2):376–386.
    1. Takahashi I, Tanaka M. Switching to latanoprost monotherapy for 24 weeks in glaucoma patients. Eur J Ophthalmol. 2004;14(5):401–406.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅